Researchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) of Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with the Agency for Science, Technology and Research (A*STAR) Bioprocessing Technology Institute (BTI) and National University Health System (NUHS), have developed a groundbreaking technology capable of extracting mesenchymal stem cells (MSCs) directly from pure bone marrow – also known as bone marrow aspirate (BMA), a pivotal source of MSCs – without dilution.
Recent Posts
- Interviews of 2025: The Big Issues
- Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy
- To Bring Cell Culture into the Future, Consider Microenvironments
- UC Irvine receives $12 million to test novel stem cell therapy for Huntington’s disease
- Novel surgical approach for retinal gene therapy shows promise


